Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid

Internal Medicine

Volumn 42, Issue 7, 2003, Pages 565-570

  Inase, Naohiko ^a   Sawada, Megumi ^a   Ohtani, Yoshio ^a   Miyake, Shuji ^a   Isogai, Susumu ^b   Sakashita, Hiroyuki ^c   Miyazaki, Yasunari ^c   Yoshizawa, Yasuyuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Tama Nanbu Hospital   (Japan)

^c TOKYO METROPOLITAN BOKUTOH HOSPITAL   (Japan)

Author keywords

CsA; CyA; Immunosuppressive; IPF; Steroid

Indexed keywords

ANTIHYPERTENSIVE AGENT; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; OXYGEN; PREDNISOLONE; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTERIAL OXYGEN TENSION; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEATH; DETERIORATION; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG WITHDRAWAL; ENCEPHALITIS VIRUS; FEMALE; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; KIDNEY DISEASE; LUNG FIBROSIS; LUNG TUBERCULOSIS; MALE; PROGNOSIS; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SURVIVAL; THORAX RADIOGRAPHY; TREATMENT OUTCOME; VIRUS ENCEPHALITIS;

EID: 0042171665     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.42.565     Document Type: Article

References (22)

1. Johnston ID, Prescott RJ, Chalmers JC, Rudd RM. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. Thorax 52: 38-44, 1997.
2. Panos RJ, Mortenson RL, Niccoli SA, King TE Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 88: 396-404, 1990.
3. Carrington CB, Gaensler EA, Coutu RE, Fitz Gerald MX, Gupta RG. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 298: 801-809, 1978.
4. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 103: 1808-1812, 1993.
5. Yoshimura K, Nakatani T, Nakamori Y, et al. Acute exacerbation in idiopathic interstitial pneumonia. Nippon Kyobu Sikkan Gakkai Zassi 22: 1012-1020, 1984 (in Japanese, Abstract in English).
6. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6: 468-475, 1976.
7. Lueck CJ, Trend P, Swash M. Cyclosporin in the management of polymyositis and dermatomyositis. J Neurol Neurosurg Psychiatry 54: 1007-1008, 1991.
8. Yocum DE, Klippel JH, Wilder RL, et al. Cyclosporin A in severe, treatment-refractory rheumatoid arthritis. A randomized study. Ann Intern Med 109: 863-869, 1988.
9. Clements PJ, Lachenbruch PA, Sterz M, et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 36: 75-83, 1993.
10. Rebuck AS, Stiller CR, Braude AC, Laupacis A, Cohen RD, Chapman KR. Cyclosporin for pulmonary sarcoidosis. Lancet 1: 1174, 1984.
11. Gruhn WB, Diaz-Buxo JA. Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis. J Rheumatol 14: 1045-1047, 1987.
12. Alegre J, Teran J, Alvarez B, Viejo JL. Successful use of cyclosporine for the treatment of aggressive pulmonary fibrosis in a patient with rheumatoid arthritis. Arthritis Rheum 33: 1594-1596, 1990.
13. Moolman JA, Bardin PG, Rossouw DJ, Joubert JR. Cyclosporin as a treatment for interstitial lung disease of unknown aetiology. Thorax 46: 592-595, 1991.
14. Alton EW, Johnson M, Turner-Warwick M. Advanced cryptogenic fibrosing alveolitis: preliminary report on treatment with cyclosporin A. Respir Med 83: 277-279, 1989.
15. Dayton CS, Schwartz DA, Helmers RA, et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for further studies. Chest 103: 69-73, 1993.
16. Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 80: S40-S45, 1996.
17. Drath DB, Kahan BD. Alterations in rat pulmonary macrophage function by the immunosuppressive agents cyclosporine, azathioprine, and prednisolone. Transplantation 35: 588-592, 1983.
18. Kumar RK, Lykke AW. Messages and handshakes: cellular interactions in pulmonary fibrosis. Pathology 27: 18-26, 1995.
19. Northrop JP, Crabtree GR, Mattila PS. Negative regulation of interleukin 2 transcription by the glucocorticoid receptor. J Exp Med 175: 1235-1245, 1992.
20. Raghu G. Interstitial lung disease: a diagnostic approach. Are CT scan and lung biopsy indicated in every patient? Am J Respir Crit Care Med 151: 909-914, 1995.
21. Tung KT, Wells AU, Rubens MB, Kirk JM, du Bois RM, Hansell DM. Accuracy of the typical computed tomographic appearances of fibrosing alveolitis. Thorax 48: 334-338, 1993.
22. Kennedy MS, Yee GC, McGuire TR, Leonard TM, Crowley JJ, Deeg HJ. Correlation of serum cyclosporine concentration with renal dysfunction in marrow transplant. recipients. Transplantation 40: 249-253, 1985.